.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB14_SebelipaseAlfa.SebelipaseAlfa .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB14_SebelipaseAlfa.SebelipaseAlfa| name: | SebelipaseAlfa | |
| ATC code: | A16AB14 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 1 | mg |
| volume of distribution: | 2.7 | L |
| clearance: | 0.19 | L/h |
| other parameters in model implementation | ||
Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme replacement therapy indicated for the treatment of lysosomal acid lipase deficiency (LAL-D), a rare genetic disorder causing the accumulation of cholesteryl esters and triglycerides. It is approved for use in both pediatric and adult patients with LAL-D.
Pharmacokinetic parameters reported for adult and pediatric (≥8 years) patients with LAL-D receiving intravenous sebelipase alfa at a dose of 1 mg/kg; values are geometric mean population PK model parameters from the published study.